Page last updated: 2024-10-29

ifosfamide and Hematuria

ifosfamide has been researched along with Hematuria in 43 studies

Hematuria: Presence of blood in the urine.

Research Excerpts

ExcerptRelevanceReference
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."9.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide."9.06Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987)
"The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically."7.67Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."7.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy."5.08Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995)
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."5.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide."5.06Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987)
" Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy."3.71U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002)
"The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically."3.67Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."3.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna."2.70Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001)
"Ifosfamide was administered by intravenous drip infusion at a daily dose of 2 g/m2 for 5 consecutive days, and mesna was intravenously administered at 20% of the ifosfamide dose, three times daily for 5 consecutive days."2.67Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. ( Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Kodama, N; Masuda, N; Nakamura, S; Negoro, S; Nishio, H; Ohnoshi, T, 1991)
" This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide."2.39Oral administration of mesna with ifosfamide. ( Goren, MP, 1996)
"Ifosfamide dosage was reduced solely for urothelial toxicity in 11 patients receiving NAC compared with none of the patients receiving mesna (p < 0."1.28Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors. ( Einhorn, LH; Langefeld, C; Loehrer, PJ; Munshi, NC; Neuman, A; Nichols, CR; Roth, BJ; Sledge, G; Walsh, WB; Williams, SD, 1992)
"Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid."1.27Ifosfamide treatment of advanced ovarian cancer. ( Arraztoa, J; Madrid, J; Wild, R; Yazigi, R, 1984)
"Forty-seven patients with Hodgkin's disease in relapse were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide)."1.27MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS, 1987)
"Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4."1.26Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978)
"Ifosfamide was given in i."1.26Reduction of ifosfamide toxicity using dose fractionation. ( Bodey, GP; Freireich, EJ; McCredie, KB; McKelvey, EM; Rodriguez, V; Tashima, CK, 1976)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-199029 (67.44)18.7374
1990's10 (23.26)18.2507
2000's2 (4.65)29.6817
2010's1 (2.33)24.3611
2020's1 (2.33)2.80

Authors

AuthorsStudies
Howe, AS1
Pearce, J1
Lian, F1
Ribbons, L1
Chumbalkar, V1
Nazeer, T1
Kogan, BA1
Ramirez, MD1
Mertens, AC1
Esiashvili, N1
Meacham, LR1
Wasilewski-Masker, K1
Cohen, MH3
Dagher, R1
Griebel, DJ1
Ibrahim, A1
Martin, A1
Scher, NS1
Sokol, GH1
Williams, GA1
Pazdur, R1
Bryant, BM1
Jarman, M1
Ford, HT1
Smith, IE1
Harrison, EF4
Hawke, JE2
Hunter, HL4
Costanzi, JJ4
Morgan, LR5
Plotkin, D2
Tucker, WG2
Worrall, PM2
Hokanson, J1
Mukouda, K1
Morikawa, E1
Hasegawa, K1
Noumi, K1
Ohmura, T1
Mishima, Y1
Kawamoto, M1
Inagaki, A1
Kamitsuna, A1
Yamakido, M1
Nishimoto, Y1
Koyama, T1
Katsuta, S1
Burkert, H2
Yazigi, R1
Wild, R1
Madrid, J1
Arraztoa, J1
Czownicki, Z1
Utracka-Hutka, B1
Slavik, M1
Saiers, JH1
Holoye, PY1
Duelge, J1
Hansen, RM1
Ritch, PS1
Anderson, T1
Loehrer, PJ3
Williams, SD3
Einhorn, LH3
Donley, PJ2
Rodriguez, V2
Cabanillas, F2
Bodey, GP2
Freireich, EJ2
Dinçol, D1
Içli, F1
Karaoğuz, H1
Cay, F1
Arican, A1
Demirkazik, A1
Akbulut, H1
Bui, BN1
Chevallier, B1
Chevreau, C1
Krakowski, I1
Peny, AM1
Thyss, A1
Maugard-Louboutin, C1
Cupissol, D1
Fargeot, P1
Bonichon, F1
Cassidy, J1
Kaye, SB1
Goren, MP2
Shepherd, FA1
Latreille, J1
Paul, K1
Eisenhauer, E1
Pectasides, D1
Aravantinos, G1
Kalofonos, H1
Kiamouris, C1
Bafaloukos, D1
Xiros, N1
Nicolaides, C1
Visvikis, A1
Dimopoulos, MA1
Schnitker, J1
Fichtner, E1
Marti, C1
Steiner, R1
Viollier, AF1
Gagliano, R1
Loukas, D1
Panettiere, FJ1
Hokanson, JA1
Nelson, RL2
Creaven, PJ2
Fossieck, BE1
McCredie, KB1
McKelvey, EM1
Tashima, CK1
Allen, LM1
Munshi, NC1
Langefeld, C1
Sledge, G1
Nichols, CR1
Roth, BJ1
Neuman, A1
Walsh, WB1
Lokich, I1
Anderson, N1
Bern, M1
Moore, C1
Fukuoka, M1
Negoro, S1
Masuda, N1
Furuse, K1
Kawahara, M1
Kodama, N1
Ikegami, H1
Nakamura, S1
Nishio, H1
Ohnoshi, T1
Iwasaku-Fujimoto, M1
Fujiwara, F1
Todo, S1
Morioka, Y1
Imashuku, S1
Munshi, N1
Antman, KH1
Ryan, L1
Elias, A1
Sherman, D1
Grier, HE1
Patterson, WP1
Khojasteh, A1
Andriole, GL1
Sandlund, JT1
Miser, JS1
Arasi, V1
Linehan, M1
Magrath, IT1
Pratt, CB1
Case, DC1
Anderson, J1
Ervin, TJ1
Gottlieb, A1
Li, GC1
Brock, N1
Li, JQ1
Guan, ZZ1
He, YJ1
de Kraker, J1
Pritchard, J1
Hartmann, O1
Ninane, J1
Hagemeister, FB1
Tannir, N1
McLaughlin, P1
Salvador, P1
Riggs, S1
Velasquez, WS1

Reviews

1 review available for ifosfamide and Hematuria

ArticleYear
Oral administration of mesna with ifosfamide.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administrat

1996

Trials

14 trials available for ifosfamide and Hematuria

ArticleYear
Yield of Urinalysis Screening in Pediatric Cancer Survivors.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Glycosuri

2016
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
    Lancet (London, England), 1980, Sep-27, Volume: 2, Issue:8196

    Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Hu

1980
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cl

1982
Clinical overview of mesna.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap

1983
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Nowotwory, 1981, Volume: 30, Issue:4

    Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol

1981
Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity.
    European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:1

    Topics: Acetylcysteine; Antineoplastic Agents; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Lung Neoplas

1982
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met

1995
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co

1996
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He

2001
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    European journal of cancer, 1976, Volume: 12, Issue:3

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul

1976
Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
    Cancer, 1991, Feb-15, Volume: 67, Issue:4

    Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; I

1991
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
    Journal of cancer research and clinical oncology, 1991, Volume: 117, Issue:5

    Topics: Adult; Aged; Double-Blind Method; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna

1991
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human

1989
Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.
    Pediatric hematology and oncology, 1987, Volume: 4, Issue:2

    Topics: Bone Marrow Diseases; Child; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Neuroblas

1987

Other Studies

28 other studies available for ifosfamide and Hematuria

ArticleYear
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo

2021
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph

2002
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati

1982
[Ifosfamide in the treatment of small cell carcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5

    Topics: Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Cystitis; Drug Administration Schedule; Drug T

1983
Ifosfamide treatment of advanced ovarian cancer.
    Obstetrics and gynecology, 1984, Volume: 63, Issue:2

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Middle Aged;

1984
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose

1983
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela

1983
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin

1983
The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Acetylcysteine; Administration, Oral; Cyclophosphamide; Female; Hematuria; Humans; Ifosfamide; Lung

1982
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans;

1982
Studies with ifosfamide in patients with malignant lymphoma.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; He

1982
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar

1995
An unusual case of haematuria.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide

1993
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1979, Jun-01, Volume: 121, Issue:22

    Topics: Adolescent; Adult; Aged; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Gastrointestinal Dise

1979
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Schweizerische medizinische Wochenschrift, 1979, Dec-08, Volume: 109, Issue:47

    Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste

1979
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
    Cancer, 1978, Volume: 41, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos

1978
Reduction of ifosfamide toxicity using dose fractionation.
    Cancer research, 1976, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans;

1976
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
    Cancer treatment reports, 1976, Volume: 60, Issue:4

    Topics: Alkylation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug E

1976
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
    Investigational new drugs, 1992, Volume: 10, Issue:3

    Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dysgerminoma; Etoposide;

1992
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:3 Pt 1

    Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia;

1990
Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Cancer investigation, 1990, Volume: 8, Issue:2

    Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematuria; Humans;

1990
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
    Cancer, 1989, Nov-15, Volume: 64, Issue:10

    Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous

1989
Ifosfamide-induced renal tubular defects.
    Cancer, 1989, Feb-15, Volume: 63, Issue:4

    Topics: Hematuria; Humans; Hydrogen-Ion Concentration; Ifosfamide; Kidney Diseases; Kidney Tubules; Lymphoma

1989
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag

1987
Ifosfamide/mesna and hematuria.
    Cancer treatment reports, 1987, Volume: 71, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Hematuri

1987
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Medical and pediatric oncology, 1988, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans

1988
Ifosfamide and Mesna in advanced malignancies.
    Chinese medical journal, 1988, Volume: 101, Issue:3

    Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom

1988
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematologic Di

1987